Yvon Julé, J Pulm Respir Med 2018, Volume 8
DOI: 10.4172/2161-105X-C2-029

7th International Chronic Obstructive Pulmonary Disease Conference

October 22-23, 2018 | Rome, Italy

Yvon Julé

Biocellvia, France

About the numerical histological imaging for COPD preclinical study: A huge help in terms of accuracy, reliability and speed

The structural changes in lung tissue induced during COPD are often assessed by scoring or semi-automatic measures that are closely dependent on the experimenter. This inevitably generates large intra- and inter-variability that impact negatively on the accuracy and reliability of results. To overcome this dependency, we have developed within Biocellvia's society fully automated digital analysis assays specifically dedicated to the evaluation of emphysema, asthma and small airway remodeling (SAR). Biocellvia's assays, based on a multiparametric assessment of pulmonary structural changes, represent a significant advance in the evaluation of COPD in terms of accuracy, reliability, reproducibility and speed. They are an invaluable aid both for basic research and for the development of candidate molecules by pharma companies.



Recent Publications

1. Michaudel C, Fauconnier L, Julé Y, et al. (2018) Functional and morphological differences of the lung upon acute and chronic ozone exposure in mice. Scientific Reports 8(1):10611.
2. Jean-Claude Gilhodes, Yvon Julé, et al. (2017) Quantification of pulmonary fibrosis in a bleomycin mouse model using automated histological image analysis. PLOS One 12(1): e0170561..

Biography

Yvon Julé is Chief Scientific Officer at Biocellvia. He co-founded this French start-up with his son, Olivier Julé. He is Professor of Biology at Aix-Marseille University where he taught for 20 years. Previously, he was Director of research at CNRS, in France. He has written more than 60 scientific publications about respiratory diseases (COPD, pulmonary fibrosis), central nervous system and neurodegenerative diseases too. He dedicates his long experience to the development of digital imaging analysis programs based on machine-learning in order to accelerate drug discovery on diseases which unmet medical needs.

yvon.jule@biocellvia.com